The FDA Panel will be reviewing a competitor's opthalmic (eye) drug on Friday, June 26th. If the Panel recommends the drug for approval and if it is eventually approved, the drug could take a sizable bit out of ACL's revenues. To read about our opinon on the FDA Panel's upcoming outcome, the drug, the disease, the market, and the competitors, get a FREE report at: http://www.newbiomedicine.com